Secondary pharmacodynamics examines effects of an investigational agent that are not related to its intended therapeutic target. It thus provides insight into selectivity beyond the desired target molecule and can help identify undesirable effects at an early stage. It is particularly important for clinical development when such off-target effects could become relevant at the expected exposures.<\/p>\n
According to ICH S7A, secondary pharmacodynamic studies cover mechanisms of action or effects of a substance that are not related to its intended therapeutic target. These investigations were previously sometimes included under general pharmacology. They can encompass binding to related receptors, enzymes, ion channels, or transporters, as well as functional responses in suitable test systems.<\/p>\n
The EMA requires a critical assessment and documentation of selectivity, specificity, and secondary pharmacodynamics for first-in-human programs. In vitro studies using human and animal material, along with relevant in vivo models, help to understand the strength and steepness of a dose-response relationship. An observed binding is only meaningful for risk assessment once its functional relevance and the anticipated exposure are taken into account.<\/p>\n
A secondary pharmacodynamic signal can influence species selection, the nonclinical safety strategy, and clinical monitoring. For example, if an effect on a physiologically significant ion channel is plausible, this may call for targeted safety pharmacology. The signal does not yet prove clinical harm but marks a hypothesis that must be evaluated based on concentrations, target tissue, and functional effect.<\/p>\n
For dose planning, secondary pharmacology is combined with PK\/PD data. This makes it possible to assess whether concentrations associated with an off-target effect could fall within the intended dosing range. Uncertainty increases in cases of prolonged target binding, nonlinear exposure, or high potency; the EMA explicitly identifies such properties as relevant considerations in nonclinical pharmacological characterization.<\/p>\n
Primary pharmacodynamics refers to the mechanism of action and effects at the intended therapeutic target. Secondary pharmacodynamics, by contrast, focuses on other targets. The categories are thus distinguished by their relationship to the therapeutic target, not by whether a finding is beneficial or undesirable. The existing pharmacodynamics entry describes the broader concept.<\/p>\n
Safety pharmacology is also not synonymous with secondary pharmacology. According to ICH S7A, it examines potentially undesirable pharmacodynamic effects on physiological functions at and above therapeutic exposure. Secondary findings can prompt or complement this examination, but safety pharmacology is focused on functional safety risks and follows its own core battery.<\/p>\n
The selection of secondary targets should be guided by the type of active substance and its primary mechanism. For a kinase inhibitor, related kinases and signaling pathways may be essential, whereas for an antibody, binding to similar epitopes or tissue distribution patterns may be the main focus. A broadly designed panel without reference to the achieved concentration, on the other hand, generates findings whose clinical relevance is often difficult to assess.<\/p>\n
Negative results are only meaningful within the range tested. They show that no relevant effect was detectable under the conditions used, but they do not prove complete selectivity across all organs or metabolites. Documentation must therefore clearly state the test system, concentration range, reference substances, and limits of detection.<\/p>\n
Secondary pharmacology may also warrant restricting the choice of concomitant clinical medication. For example, if an off-target mechanism could affect cardiac repolarization, pharmacodynamic interactions\u2014not just metabolic interactions\u2014must be considered in risk management.<\/p>\n
When translating findings to humans, the tissue distribution of the secondary target must also be examined. A mechanism detectable in cell-based assays gains significance if the relevant target is present in clinically accessible organs and the relevant concentration is plausible there.<\/p>\n
The secondary pharmacodynamic assessment translates into the study protocol as targeted exclusion criteria, safety parameters, and dose limits. A plausible off-target effect can justify additional ECGs, laboratory analyses, or symptom-oriented examinations. For interpreting events, it is crucial whether they align in timing and exposure with the expected secondary mechanism.<\/p>\n
Full-service CROs such as Mediconomics support the integration of in vitro profiling, PK\/PD modeling, and clinical safety monitoring. Medical writing can translate the off-target rationale into the Investigator’s Brochure, while medical monitoring and data management embed the resulting capture and evaluation pathways into study operations.<\/p>\n
Is every binding to another molecule considered secondary pharmacodynamics?<\/strong><\/p>\n An observed binding is a starting point; the assessment must also consider whether it results in a functional effect and whether this is achievable at relevant exposure.<\/p>\n Can secondary pharmacodynamics be therapeutically desirable?<\/strong><\/p>\n The term describes the lack of relationship to the primary therapeutic target. Whether an effect is later utilized or assessed as a risk is a separate development decision.<\/p>\n Why isn’t a safety pharmacology program sufficient on its own?<\/strong><\/p>\n The core battery examines certain vital functions; the secondary pharmacodynamic profile can reveal additional targets and mechanisms beyond these.<\/p>\n Secondary pharmacodynamics examines effects of an investigational agent that are not related to its intended therapeutic target. It thus provides insight into selectivity beyond the desired target molecule and can help identify undesirable effects at an early stage. It is particularly important for clinical development when such off-target effects could become relevant at the expected […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[27],"class_list":["post-8184","glossary","type-glossary","status-publish","hentry","glossary-cat-nichtklinik-pharmakologie"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8184\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8184"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n